A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.

Trial Profile

A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Momelotinib (Primary)
  • Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 08 Dec 2015 Results of exploratory analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 May 2014 Planned End Date changed from 1 Dec 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top